This hypothesis posits that mild hyperbaric oxidative stress activates Nrf2-ARE transcriptional programs, upregulating SOD1, catalase, GPx1, and HO-1 without causing cumulative oxidative injury. It provides the most direct framework for parameter optimization via dose-response mapping and represents the strongest balance of mechanistic plausibility and parameter tractability. The hormetic dose-window concept directly addresses the knowledge gap about optimal HBOT parameters.
Curated pathway from expert analysis
flowchart TD
A["Oxidative Stress<br/>ROS/Electrophiles"]
B["KEAP1 Cysteine Oxidation<br/>Sensor Inactivation"]
C["NRF2 Release<br/>KEAP1-NRF2 Dissociation"]
D["NRF2 Nuclear Translocation<br/>ARE Binding"]
E["Phase II Enzyme Expression<br/>HO1/NQO1/GCLC/GCLM"]
F["GSH Synthesis<br/>Antioxidant Pool Replenished"]
G["ROS Detoxification<br/>Cytoprotection"]
H["NRF2 Reduced in AD<br/>Oxidative Vulnerability"]
A --> B
B --> C
C --> D
D --> E
E --> F
F --> G
H -.->|"impairs"| C
style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style G fill:#1b5e20,stroke:#81c784,color:#81c784
style H fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9aNo linked papers recorded for this hypothesis yet.
No curated PDB or AlphaFold mapping for NFE2L2 yet. Search RCSB →
Median TPM across 13 brain regions for NFE2L2 (Nrf2) from GTEx v10.
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for NFE2L2 (Nrf2).
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF APP/PS1 transgenic mice receive HBOT at 1.5 ATA for 60 min daily for 4 weeks THEN hippocampal and cortical protein levels of SOD1, catalase, GPx1, and HO-1 will increase by ≥40% without elevation o | Coordinated upregulation of all four antioxidant enzymes (SOD1, CAT, GPx1, HO-1) by ≥40% via Western blot/ELISA, with no change or decrease in oxidative damage | — no observation — | pending | 0.72 |
| IF humans with subjective cognitive decline receive HBOT at 1.5 ATA for 60 min once daily (5 days/week for 8 weeks) THEN peripheral blood mononuclear cell Nrf2 nuclear translocation and mRNA expressio | Nrf2 pathway activation biomarker panel (HO-1, NQO1, GCLC mRNA) will show ≥30% upregulation in the HBOT 1.5 ATA group versus sham control, with concurrent incre | — no observation — | pending | 0.65 |